Key facts
- Global healthcare companies are investing billions to expand US manufacturing and research.
- Pfizer committed $70 billion to US R&D and manufacturing.
- GSK plans to invest $30 billion in US R&D and supply chain infrastructure over five years.
- Eli Lilly plans to spend at least $27 billion on four US plants.
- Johnson & Johnson plans to raise US investments by 25% to $55 billion over four years.
- Roche announced a $50 billion investment in the US over five years, plus an additional $550 million for its Indianapolis hub.
Global healthcare companies are announcing substantial investments in the United States, committing billions of dollars to expand their manufacturing and research operations. These moves are seen as a response to a shifting trade environment and an effort to mitigate supply-chain risks.
Drugmakers including Eli Lilly, Pfizer, AstraZeneca, and Roche are among those announcing significant US investments, totaling approximately $500 billion. These commitments aim to strengthen domestic infrastructure and reassure investors.
Pfizer has agreed to invest $70 billion in US research and development and manufacturing, receiving a three-year exemption from pharmaceutical-targeted tariffs. GSK plans to invest $30 billion in US research and development and supply chain infrastructure over five years. Eli Lilly announced plans to spend at least $27 billion to build four US plants to expand production and bolster medical supply chains, including a $3.5 billion facility in Pennsylvania. Johnson & Johnson intends to increase its US investments by 25% to $55 billion over the next four years, planning to build four plants. Roche announced a $50 billion investment in the US over five years, with an additional $550 million for its Indianapolis diagnostics manufacturing hub, and plans to more than double its investment in its Holly Springs, North Carolina, drug manufacturing facility to about $2 billion.
AstraZeneca will invest $50 billion in US manufacturing by 2030, funding a new drug substance facility in Virginia and expansions in other states. Novartis plans to spend $23 billion over five years to build and expand 10 facilities in the US, including six new manufacturing plants. Sanofi intends to invest at least $20 billion in the US through 2030 to boost manufacturing and research. Biogen will invest an additional $2 billion in its North Carolina manufacturing plants. Merck is building a $3 billion pharmaceutical manufacturing plant in Virginia as part of a broader $70 billion investment, and will invest $1 billion in a Delaware plant for biologics and cancer drug Keytruda. Merck's animal health unit will invest $895 million to expand its Kansas site as part of a $9 billion US investment through 2028. Amgen plans to invest $900 million to expand its Ohio manufacturing facility and committed $1 billion to build a second facility in Holly Springs, North Carolina. Amgen is also investing more than $600 million to build a new research and development center in California and $650 million to expand drug manufacturing in Puerto Rico. Novo Nordisk stated its strong US manufacturing footprint positions it well for tariff challenges. AbbVie committed $100 billion over the next decade to US-based research and development, and plans to invest $380 million to build two manufacturing facilities in Illinois. Gilead Sciences announced $11 billion in new planned investment in the US, bringing its total pledged investment to $32 billion, and is developing three sites. Bristol Myers Squibb will invest about $2.3 billion to build a new drug manufacturing facility in Houston, Texas, as part of its broader $40 billion US investment commitment. Indian drugmaker Cipla is expanding its US manufacturing footprint for respiratory products. Australia's CSL will invest $1.5 billion in the US over five years to manufacture plasma-derived therapies. Becton Dickinson plans to invest $19 billion in the US over several years.